证券代码：688443 证券简称：智翔金泰 公告编号：2025-026 重庆智翔金泰生物制药股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 92 | | --- | --- | | 普通股股东人数 | 92 | | 2、出席会议的股东所持有的表决权数量 | 223,360,127 | | 普通股股东所持有表决权数量 | 223,360,127 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 61.0467 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 61.0467 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 1、 议案名称：《关于公司 2024 年度董事会工作报告的议案》 审议结果：通过 本次股东大会由董事会召集，会议采取现场投票和网络投票相结合的表决方 （一） 股东大会召开 ...

证券代码：688443 证券简称：智翔金泰 公告编号：2025-025 重庆智翔金泰生物制药股份有限公司 首次公开发行战略配售限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发战略配售股份（限售期 24 月）；股票认购方式 为网下，上市股数为2,639,915股。本公司确认，上市流通数量等于该限售期的全 部战略配售股份数量。 本次股票上市流通总数为2,639,915股。 本次股票上市流通日期为2025 年 6 月 20 日。 一、本次限售股上市类型 根据中国证券监督管理委员会《关于同意重庆智翔金泰生物制药股份有限公 司首次公开发行股票注册的批复》（证监许可〔2023〕725 号），重庆智翔金泰生 物制药股份有限公司（以下简称"公司"或"智翔金泰"）首次公开发行人民币 普通股 91,680,000 股，并于 2023 年 6 月 20 日在上海证券交易所科创板挂牌上市。 公司首次公开发行股票完成后，总股本为 366,680,000 股，其中有限售条件流通股 为 283, ...

国泰海通证券股份有限公司 关于重庆智翔金泰生物制药股份有限公司 一、本次限售股上市类型 根据中国证券监督管理委员会《关于同意重庆智翔金泰生物制药股份有限公 司首次公开发行股票注册的批复》（证监许可〔2023〕725 号），重庆智翔金泰生 物制药股份有限公司（以下简称"公司"或"智翔金泰"）首次公开发行人民币普通 股 91,680,000 股，并于 2023 年 6 月 20 日在上海证券交易所科创板挂牌上市。公 司首次公开发行股票完成后，总股本为 366,680,000 股，其中有限售条件流通股 为 283,912,912 股，占本公司发行后总股本的 77.4280%，无限售条件流通股为 82,767,088 股，占本公司发行后总股本的 22.5720%。 首次公开发行战略配售限售股上市流通的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 重庆智翔金泰生物制药股份有限公司（以下简称"智翔金泰"或"公司"）首次 公开发行股票并在科创板上市及持续督导的保荐机构，根据《证券发行上市保荐 业务管理办法》《上海证券交易所科创板股票上市规则》等法律法规的相关规定， 对智翔金泰首次公开发行战略 ...

Core Viewpoint - The 2024 Annual General Meeting of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. outlines the procedures and agenda for the meeting, including various proposals for shareholder approval, reflecting the company's operational status and future plans [1][2][3]. Meeting Procedures - Shareholders or their representatives must arrive 30 minutes before the meeting and present identification for attendance verification [2]. - Only authorized personnel, including shareholders, directors, supervisors, and invited guests, are allowed to enter the meeting venue [1][2]. - Shareholders have the right to speak, inquire, and vote during the meeting, with specific rules governing the order and duration of speeches [2][3]. Voting and Proposals - The meeting will utilize both on-site and online voting methods, with specific timeframes for each [4][6]. - Key proposals include the 2024 Board of Directors' work report, the 2024 Supervisory Board's work report, and the 2024 annual financial report, all of which have been approved by the board and supervisory committee [5][8][9]. Financial Performance - The company reported a total asset decrease of 12.49% year-on-year, with total liabilities increasing by 25.83% [21][25]. - The net profit for the year was -79.73 million yuan, a slight improvement from the previous year's loss [21]. - Operating revenue reached 30.10 million yuan, a significant increase of 2384.11% compared to the previous year, primarily due to the launch of the product "Sailiqi Monoclonal Antibody Injection" [21][24]. Expense Analysis - Sales expenses surged by 1030.29% to 117.89 million yuan, attributed to the expansion of the sales team and marketing efforts for the new product [22][23]. - Management expenses decreased by 17.60%, while R&D expenses slightly reduced by 1.71% [22][23]. - Financial expenses showed a significant decrease of 313.63%, mainly due to increased interest income from temporarily idle funds [24]. Future Plans - The company plans to apply for a new comprehensive credit limit of up to 2.5 billion yuan to support its operational goals [12][13]. - Proposals for the 2025 director and supervisor remuneration plans have been outlined, reflecting the company's commitment to aligning compensation with performance [10][12].

股票代码：688443 股票简称：智翔金泰 重庆智翔金泰生物制药股份有限公司 2024 年年度股东大会会议资料 2025 年 6 月 重庆智翔金泰生物制药股份有限公司 2024 年年度股东大会会议资料 目录 | 重庆智翔金泰生物制药股份有限公司 2024 年年度股东大会会议须知 | | 1 | | --- | --- | --- | | 重庆智翔金泰生物制药股份有限公司 2024 年年度股东大会会议议程 | | 3 | | 重庆智翔金泰生物制药股份有限公司 2024 年年度股东大会会议议案 | | 5 | | 议案一：关于公司 年度董事会工作报告的议案 | 2024 | 5 | | 议案二：关于公司《2024 年度监事会工作报告》的议案 | | 6 | | 议案三：关于公司《2024 年年度报告》及其摘要的议案 | | 7 | | 议案四：关于公司《2024 年度财务决算报告》的议案 | | 8 | | 议案五：关于公司 年度利润分配方案的议案 | 2024 | 9 | | 议案六：关于续聘公司 年度审计机构的议案 | 2025 | 10 | | 议案七：关于公司 年度董事薪酬方案的议案 11 | 2025 ...

Investment Rating - The investment rating for the company is "Buy" [7] Core Viewpoints - The report is optimistic about the commercialization prospects of the company's products, including the monoclonal antibody "Sai Li Qi" and the bispecific antibodies GR2002 and GR1803, anticipating data readouts that could enhance valuation [1] - The company achieved significant revenue growth in 2024, with total revenue reaching 30.10 million yuan, and a slight narrowing of net losses to 797 million yuan [1] - The company has a differentiated pipeline with key products progressing steadily, including the approval of Sai Li Qi for moderate to severe plaque psoriasis and ankylosing spondylitis [1][2] Financial Performance - In Q1 2025, the company reported revenue of 20.16 million yuan and a net loss of 121 million yuan, with R&D expenses at 10.30 million yuan [1] - Revenue projections for 2025-2027 are estimated at 199 million yuan, 533 million yuan, and 1.07 billion yuan respectively, reflecting a strong growth trajectory [4][6] - The company maintains high R&D expenditure, with 610 million yuan in 2024, indicating a commitment to innovation [1] Pipeline Development - The GR1802 monoclonal antibody is progressing through clinical trials for multiple indications, with significant market potential [2] - The GR1801 rabies virus antibody is currently under review for market approval, with promising commercial prospects [2] - Other pipeline products, including GR2001 and GR1803, are advancing through clinical stages and partnerships, demonstrating the company's innovative capabilities [3]

Investment Rating - The investment rating for the company is "Buy" [7] Core Views - The report is optimistic about the commercialization prospects of the company's products, including the monoclonal antibody "Sailiqi" and the bispecific antibody for rabies [1] - The company achieved significant revenue growth in 2024, with total revenue reaching 30.10 million yuan, and a slight narrowing of net losses compared to the previous year [1] - The company is advancing its pipeline with a focus on differentiated indications, with key products expected to enter commercialization phases [1][2] Financial Performance - In 2024, the company reported a revenue of 30.10 million yuan, a substantial increase from the previous year, while the net profit attributable to the parent company was a loss of 797.27 million yuan [4][6] - For Q1 2025, the company generated revenue of 20.16 million yuan, with a net loss of 121 million yuan [1] - Revenue projections for 2025 to 2027 are estimated at 199 million yuan, 533 million yuan, and 1.07 billion yuan respectively, indicating strong growth potential [4][6] Pipeline Development - The "Sailiqi" monoclonal antibody has received approvals for two indications, with expectations for significant sales growth in 2025 and 2026 [1] - The bispecific antibody GR1803 has entered a collaboration agreement with Cullinan Therapeutics, with a total transaction value of 712 million USD, currently in Phase II clinical trials [3] - Other pipeline products, including GR1802 and GR1801, are progressing through clinical trials, with GR1802 targeting multiple indications and GR1801 being a promising rabies treatment [2][3]

Core Viewpoint - The collaboration between Zhixiang Jintai and Cullinan Therapeutics aims to accelerate the global development of GR1803, a bispecific antibody for treating relapsed/refractory multiple myeloma, marking a significant milestone in Zhixiang Jintai's global strategy and innovation transformation [2]. Group 1 - Zhixiang Jintai announced an overseas licensing agreement with Cullinan Therapeutics, granting Cullinan global development, production, and commercialization rights for GR1803 outside Greater China, while retaining rights in mainland China [1]. - The agreement includes an upfront payment of $20 million, potential milestone payments up to $692 million, and tiered royalties based on net sales outside Greater China [1]. - GR1803 is currently in Phase 2 clinical trials and was included in the list of breakthrough therapies by the Chinese National Medical Products Administration [2]. Group 2 - SinoMed, established in March 2022, provides business development services for biopharmaceutical companies seeking overseas collaborations, with a team experienced in cross-border licensing transactions [3]. - The SinoMed team has evaluated over 300 projects and facilitated collaborations with more than 20 domestic companies, completing transactions for three projects across various therapeutic areas [3].

协议内容摘要 2025 年 6 月 4 日，重庆智翔金泰生物制药股份有限公司（以下简称"智翔 金泰"或"公司"）与 Cullinan Therapeutics, Inc.（纳斯达克股票代码：CGEM；以 下简称"Cullinan"）签署授权许可与商业化协议，就 GR1803 注射液达成独家许 可与合作协议。GR1803 是一种双特异性抗体，可同时结合 BCMA 和 CD3 抗原， 从而将细胞毒性 T 细胞定向至表达 BCMA 的细胞。根据协议，Cullinan 将获得 GR1803 注射液除大中华区域（包括香港、澳门、台湾）以外区域的开发、生产、 商业化权益，智翔金泰保留大中华区域所有适应症权益。此外，智翔金泰将探索 GR1803 注射液项目在中国大陆区域的自身免疫性疾病相关的研究，根据要求启 动临床试验并将临床数据有偿授权给 Cullinan 使用。 交易标的名称：GR1803 注射液在中国以外所有疾病领域开发和商业化的独 家权利。 证券代码：688443 证券简称：智翔金泰 公告编号：2025-024 重庆智翔金泰生物制药股份有限公司 关于与Cullinan就GR1803注射液签署授权许可与商 业化协议的 ...

Core Insights - Cullinan Therapeutics has advanced its leadership in T cell engager (TCE) development for autoimmune diseases, with both a CD19 TCE and BCMA TCE in its pipeline [1] - The company has strengthened its portfolio of autoimmune programs, aiming to address a broader range of diseases while ensuring cash runway into 2028 [1][5] - Cullinan has entered into an agreement with Genrix Bio for an exclusive global license to velinotamig, a BCMAxCD3 bispecific T cell engager, which has shown promising efficacy in treating relapsed/refractory multiple myeloma [2][3] Company Developments - Velinotamig has demonstrated potential best-in-class efficacy at the Phase 2 target dose in nearly 50 patients with relapsed/refractory multiple myeloma [2] - The agreement includes an upfront license fee of $20 million, with potential future payments of up to $292 million in development and regulatory milestones, plus up to $400 million in sales-based milestones [4] - Cullinan plans to leverage data from Genrix's Phase 1 study in China to accelerate global clinical development of velinotamig in autoimmune diseases [3][4] Industry Context - T cell engagers are viewed as the next wave of innovation in autoimmune diseases, with BCMA as a promising target for a precise and potentially disease-modifying approach [3] - The collaboration with Genrix Bio is expected to enhance Cullinan's capabilities in developing therapies for autoimmune diseases, addressing the needs of a wider patient population [4][10]